Cancer diagnostics company NeoGenomics Inc (NASDAQ:NEO) confirmed on Monday that it has completed its acquisition of Pathline LLC, a laboratory in New Jersey.
This acquisition enhances NeoGenomics' commercial presence in the Northeast United States and expands access to its oncology testing services in the Tri-state area.
Pathline is CLIA, CAP and NYS certified, aligning with NeoGenomics' standards for high-quality diagnostic testing.
Through this transaction NeoGenomics broadens access to its comprehensive oncology test menu, expands its service capabilities and accelerates growth in molecular and haematology-oncology diagnostics.
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
InSysBio agrees new collaborative project with BeOne Medicines
Physiomics secures new modelling contract with Numab Therapeutics
Mabwell reports first patient dosed with 7MW4911 in US trial
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
Avacta secures FDA clearance for second pre|CISION oncology programme
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis